Sign up to save your podcasts
Or
Share Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Interview with Fabio Rosa, Co-Founder and Head of Research of Asgard Therapeutics
In this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.
View all episodes
By EIC Scaling ClubIn this interview, Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics, discusses their groundbreaking cancer therapy, AT108, which reprograms cancer cells into immune cells. Asgard has raised €30 million in Series A funding and is preparing for clinical trials by 2027. With strong scientific validation and key publications, the company is now focused on partnerships, production scaling, and investor relations to drive its innovative therapy forward.